Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib and Casdatifan Combinations in Advanced Solid Tumors and ccRCC
NCT06191796Phase 1Terminated
- Sponsor
- Exelixis, Inc.
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib and casdatifan in clear cell renal cell carcinoma (ccRCC) and solid tumor (advanced stage) (4 arms), sponsored by Exelixis, Inc. Primary endpoints: Number of participants with dose-limiting toxicities at 24 months and Objective Response Rate at 24 months. Started Jan 2024; status: terminated.
02
Drugs
zanzalintinibcasdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06191796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191796.